Initially, BARDA will give $38.5m to GSK over two years to develop GSK2251052, an investigational antibiotic against bacterial enzyme leucyl tRNA synthetase.
The funding is expected to support ongoing GSK studies and new research into biothreat pathogens such as Yersinia pestis that causes bubonic plague and Bacillus anthracis which causes anthrax.
Additional financing may be available if BARDA exercises options for future funding.